New drug duo aims to tame aggressive thyroid cancer
NCT ID NCT04171622
Summary
This study is testing whether two drugs, lenvatinib and pembrolizumab, work better together for people with advanced anaplastic thyroid cancer that cannot be removed by surgery or has spread. Lenvatinib aims to block tumor growth, while pembrolizumab helps the body's immune system attack the cancer. The main goal is to see if this combination helps patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID GLAND SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.